Régulier E, Pereira de Almeida L, Sommer B, Aebischer P, Déglon N
Institute of Neurosciences, Swiss Federal Institute of Technology Lausanne, 1015 Lausanne, Switzerland.
Hum Gene Ther. 2002 Nov 1;13(16):1981-90. doi: 10.1089/10430340260355383.
The ability to regulate gene expression constitutes a prerequisite for the development of gene therapy strategies aimed at the treatment of neurologic disorders. In the present work, we used tetracycline (Tet)-regulated lentiviral vectors to investigate the dose-dependent neuroprotective effect of human ciliary neurotrophic factor (CNTF) in the quinolinic acid (QA) model of Huntington's disease (HD). The Tet system was split in two lentiviruses, the first one containing the CNTF or green fluorescent protein (GFP) cDNAs under the control of the Tet-response element (TRE) and a second vector encoding the transactivator (tTA). Preliminary coinfection study demonstrated that 63.8% +/- 2.0% of infected cells contain at least two viral copies. Adult rats were then injected with CNTF- and GFP-expressing viral vectors followed 3 weeks later by an intrastriatal administration of QA. A significant reduction of apomorphine-induced rotations was observed in the CNTF-on group. In contrast, GFP-treated animals or CNTF-off rats displayed an ipsilateral turning behavior in response to apomorphine. A selective sparing of DARPP-32-, choline acetyltransferase (ChAT)-, and NADPH-d-positive neurons was observed in the striatum of CNTF-on rats compared to GFP animals and CNTF-off group. Enzyme-linked immunosorbent assay (ELISA) performed on striatal samples of rats sacrificed at the same time point indicated that this neuroprotective effect was associated with the production of 15.5 +/- 4.7 ng CNTF per milligram of protein whereas the residual CNTF expression in the off state (0.54 +/- 0.02 ng/mg of protein) was not sufficient to protect against QA toxicity. These results establish the proof of principle of neurotrophic factor dosing for neurodegenerative diseases and demonstrate the feasibility of lentiviral-mediated tetracycline-regulated gene transfer in the brain.
调节基因表达的能力是开发旨在治疗神经系统疾病的基因治疗策略的先决条件。在本研究中,我们使用四环素(Tet)调控的慢病毒载体,在喹啉酸(QA)诱导的亨廷顿舞蹈病(HD)模型中研究人睫状神经营养因子(CNTF)的剂量依赖性神经保护作用。Tet系统被分为两种慢病毒,第一种含有在Tet反应元件(TRE)控制下的CNTF或绿色荧光蛋白(GFP)cDNA,第二种载体编码反式激活因子(tTA)。初步共感染研究表明,63.8%±2.0%的感染细胞至少含有两个病毒拷贝。然后给成年大鼠注射表达CNTF和GFP的病毒载体,3周后进行纹状体内注射QA。在CNTF开启组中观察到阿扑吗啡诱导的旋转显著减少。相比之下,GFP处理的动物或CNTF关闭的大鼠对阿扑吗啡表现出同侧转向行为。与GFP处理的动物和CNTF关闭组相比,在CNTF开启的大鼠纹状体中观察到DARPP-32、胆碱乙酰转移酶(ChAT)和NADPH-d阳性神经元有选择性的保留。在同一时间点处死的大鼠纹状体样本上进行的酶联免疫吸附测定(ELISA)表明,这种神经保护作用与每毫克蛋白质产生15.5±4.7 ng CNTF有关,而关闭状态下残留的CNTF表达(0.54±0.02 ng/mg蛋白质)不足以保护免受QA毒性。这些结果确立了神经营养因子给药治疗神经退行性疾病的原理证明,并证明了慢病毒介导的四环素调控基因转移在大脑中的可行性。